CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
Brensocatib has demonstrated efficacy in reducing neutrophil serine protease activity and symptom burden in non-cystic fibrosis bronchiectasis. GLP-1 inhibitors show potential in managing obstructive ...
Panelists discusses how the "vicious vortex model" explains bronchiectasis pathophysiology, where airway dilatation leads to mucus stagnation, chronic infections, and neutrophilic inflammation, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results